Prostin

Quick links to important sections

Prostin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostin

Quick Facts

Feature Details
Active Ingredient Dinoprostone (Prostaglandin E2)
Drug Class Oxytocic Agent, Prostaglandin
Administration Vaginal Gel or Tablet, or Injection (depending on specific product and use)
Status Prescription Only (Rx)

What is Prostin?

Prostin is a brand name medication whose active ingredient is dinoprostone, a synthetic version of the naturally occurring hormone prostaglandin E2 (PGE2). This compound is classified as an oxytocic agent and is primarily used in obstetrics.

Therapeutic Role

Dinoprostone is clinically recognized for its ability to affect the muscular tissue of the uterus and the cervix. Its main medical application is in two distinct areas, which vary based on the specific formulation (e.g., vaginal gel, vaginal tablet, or injection):

  1. Cervical Ripening and Labor Induction: When a medical or obstetrical need for induction of labor exists, Prostin (often sold as Prostin E2) is used to help prepare the cervix. It softens, thins, and dilates the cervix, a process known as cervical ripening, making it more favorable for labor.
  2. Evacuation of Uterine Contents: Specific formulations may be used by healthcare providers for the management of conditions such as intrauterine fetal death, missed abortion, or the termination of pregnancy (in the second trimester).

Key Differentiating Features

As a prostaglandin, dinoprostone primarily functions by stimulating the myometrium (the muscle layer of the uterus) to contract, mimicking the contractions seen in natural labor. The administration of this medication is highly specialized and is restricted to hospitals or clinics with dedicated obstetric units where continuous monitoring of both the patient's uterine activity and the fetus's heart rate can be performed.

Regulatory References

  1. NIH - Dinoprostone

What side effects are possible with Prostin?

Possible Side Effects and Safety Information

The official safety profile of Prostin (alprostadil) is based on classifications from regulatory documents, detailing observed adverse effects primarily in the neonatal population for which it is indicated. The effects are often related to the drug's activity on vascular and smooth muscle tissue.


Adverse Reaction Categories

Classification Examples of Documented Adverse Reactions
Very Common Apnea (temporary cessation of breathing), Flushing
Common Bradycardia, Hypotension, Tachycardia, Cardiac Arrest, Fever, Seizures, Diarrhea, Hypothermia

These reactions are grouped into system-organ classes, with effects noted in the Cardiovascular, Respiratory, and Nervous Systems being the most frequently classified.


Serious Safety Considerations

The label documents serious adverse reactions including cardiac arrest and a heightened risk of apnea, especially in newborns with a low birth weight (less than 2.0 kg). Due to the potential for these acute events, the medication must be administered in settings where specialized pediatric intensive care and respiratory support are immediately available, as mandated by official safety restrictions.


Duration-Related Safety Patterns

Safety information notes that changes, such as cortical bone proliferation and diffuse thickening of the ductus arteriosus wall, have been associated with extended continuous use. These structural changes, which occur with longer exposure, are typically reversible following the discontinuation of the treatment.

This framework of officially documented risks guides the understanding of the medicine's highly specialized and constrained use.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the overdose manifestations and required emergency actions as documented in official government regulatory sources for the active ingredients associated with the brand name Prostin (Dinoprostone and Alprostadil).


Documented Overdose Manifestations

Active Ingredient Primary Overdose Manifestation
Dinoprostone (Obstetric Use) Uterine hypertonus or hypercontractility.
Alprostadil (Intracavernosal Use) Prolonged erection or priapism.
Alprostadil (Neonatal IV Use) Apnea, hypotension, or bradycardia.

Required Emergency Actions

Immediate medical attention must be sought for specific events that indicate an overdose or excessive pharmacological effect. For Dinoprostone, the product must be immediately stopped or removed upon any sign of sustained uterine activity or fetal distress, as this can lead to severe outcomes like uterine rupture. For Alprostadil, an erection persisting longer than four hours requires immediate medical assistance to prevent permanent tissue damage. Neonates receiving intravenous Alprostadil are closely monitored, and the infusion is discontinued immediately if apnea or bradycardia occurs, especially in infants under two kilograms. Management for overdose for both active ingredients is primarily symptomatic and supportive, as no specific antidote is known.

Therapeutic Uses of Prostin

Prostin (alprostadil) is authorized for use in newborns who have certain congenital heart defects and require the temporary maintenance of the ductus arteriosus opening. This temporary action is considered supportive care until corrective or palliative surgery can be performed.

The medication is used in situations where the infant's survival is dependent on the ductal opening to ensure adequate pulmonary or systemic blood flow. Conditions that may require this management include pulmonary atresia, tricuspid atresia, severe coarctation of the aorta, and certain types of transposition of the great vessels.

Its use is designated as palliative, not definitive therapy, serving to improve the infant's clinical status and support stability during this critical period.


Quick Fact: Relief for Impaired Circulation Prostin provides temporary support to maintain necessary blood flow in infants with specific heart conditions.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Prostin

The eligibility profile for Prostin is strictly defined by regulatory documents, which address two different active ingredients for distinct patient populations: Dinoprostone (for obstetric use) and Alprostadil (for neonatal cardiac use).


Category Dinoprostone (Obstetric Use) Alprostadil (Neonatal Use)
Populations Allowed Adult women at or near term in pregnancy for labor induction. Neonates with specific congenital heart defects.
Absolute Contraindications Hypersensitivity. History of Caesarean section or major uterine surgery. Multiparity (six or more previous term pregnancies). Active cardiac, pulmonary, renal, or hepatic disease. Hypersensitivity. Neonates with Respiratory Distress Syndrome (Hyaline Membrane Disease).
Conditional Use Caution required for patients with impaired renal or hepatic function, history of asthma, or glaucoma. Caution required in neonates with bleeding tendencies or those weighing less than 2 kg.
Age-Related Rules Only for adults (pregnant women). Not established for use in children or older adults. Neonates/Infants only. Not applicable to older age groups.

Official regulatory documents define these eligibility rules through a comprehensive structure of absolute prohibitions and explicit conditional restrictions. The two distinct indications create severely limited patient groups, ensuring the medicine is only administered within specific clinical and physiological contexts defined in the labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures Prostin’s interaction profile primarily around pharmacodynamic synergy and specific procedural constraints required by regulatory authorities.

Pharmacodynamic Interactions and Contraindications

Co-administration of dinoprostone (Prostin E2/Cervidil) with intravenous oxytocic agents is formally contraindicated by regulatory bodies due to the risk of additive uterine stimulation. Sequential use with other oxytocic agents, such as Oxytocin, may augment the uterine effect and requires specific timing separation rules. The vaginal insert formulation mandates removal at least 30 minutes prior to the administration of an intravenous oxytocic agent, while the vaginal gel requires an interval of at least 6 hours.

For injectable alprostadil (Prostin VR), co-use with anticoagulants (like warfarin or heparin) is associated with an increased propensity for bleeding.

Excipient and Pharmacokinetic Considerations

The formulation of neonatal alprostadil (Prostin VR) contains ethanol as an excipient. The official labeling documents a risk of ethanol accumulation and possible central nervous system effects, particularly when co-administered with other medicines containing alcohol or propylene glycol. This risk is amplified in the pediatric population due to lower metabolic capacity. Additionally, clearance-related exposure risks are noted in patients with impaired hepatic or renal function, which can prolong the activity and alter the interaction profile of dinoprostone.

Mechanism of Action

The mechanism of action for Prostin (Dinoprostone) involves the modulation of signaling within the prostanoid pathway through targeted receptor agonism. This action leads to two primary, coordinated effects at the cellular and tissue level, which results in its defined physiological consequences.

Prostaglandin Receptor Signaling

Prostin acts as a direct agonist for the body's natural Prostaglandin E2 ( PGE2) receptors, specifically the EP1, EP2, EP3, and EP4 subtypes, which are G protein-coupled receptors (GPCRs). This binding initiates distinct intracellular second messenger cascades (e.g., regulating cAMP and Ca^2+) thereby regulating downstream physiological activity.

Dual Physiological Mechanisms

Activation of receptors like EP1 and EP3 in the uterine wall (myometrium) influences the flow of calcium ions ( Ca^2+) within smooth muscle cells, leading to a net increase in intracellular Ca^2+. This essential molecular step triggers the contractile machinery, resulting in increased, rhythmic uterine contractions (oxytocic effect).

Separately, activation of receptors EP2 and EP4 in cervical connective tissue upregulates matrix metalloproteinases (MMPs)—enzymes that break down structural collagen fibers. This process drives the physiological change known as cervical ripening, or the softening and effacement of the cervix.

Dosage and Administration Information

Prostin refers to products containing two different prostaglandins, Dinoprostone and Alprostadil, each with distinct administration protocols that require specialized medical supervision.

The medicine is used under strict inpatient conditions, with administration patterns defined by the active ingredient and intended use:

Active Ingredient Administration Route & Form Dosing and Scheduling Principles
Dinoprostone (Obstetric Use) Vaginal (Insert, Gel, Suppository) or Endocervical (Gel). Single-Dose or Timed Intermittent Use. A single 10 mg vaginal insert is typically administered once, or a 0.5 mg endocervical gel dose may be repeated after 6 hours, not to exceed 1.5 mg in 24 hours. The patient must remain supine for a specified period following administration.
Alprostadil (Neonatal Use) Continuous Intravenous (IV) Infusion (into a large vein or umbilical artery catheter). Weight-Based and Continuous. Administration begins at a rate of 0.05 to 0.1 micrograms/kg/minute. The rate must be reduced to the lowest effective maintenance dose upon response, as this is a temporary, palliative measure in a monitored intensive care setting.

For Alprostadil, the solution concentrate must be diluted immediately before administration with a compatible IV fluid, such as dextrose or sodium chloride injection. For Dinoprostone, there is a mandatory waiting period before other oxytocic agents may be introduced. All procedures, including the removal of the vaginal insert upon active labor, are highly standardized to ensure precise use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Prostin


Evidence for Use in Cervical Ripening and Labor Induction (Dinoprostone)

The research that informed the clinical evaluation of dinoprostone (often known as Prostin E2) for preparing the cervix and starting labor was evaluated in a large number of Randomized Controlled Trials (RCTs). These trials were compiled into numerous Meta-Analyses. Researchers examined how dinoprostone administration was associated with changes in the Bishop score—a way to measure the readiness of the cervix. Studies also monitored outcomes related to the overall labor process, such as the total time interval that elapsed until delivery and whether an individual needed another medicine to stimulate contractions.

The findings from these trials describe patterns observed in the studies regarding changes in cervical readiness after administration. The research base for this specific use consists of numerous studies. Despite the extensive research, the findings were mixed when dinoprostone was studied for comparison against some other agents, and the way the drug is administered vary across studies, which may make direct comparisons challenging.


Evidence for Use in Evacuation of Uterine Contents (Dinoprostone)

Dinoprostone was studied for its role in managing conditions such as fetal death in the second trimester. Research here includes a mix of RCTs and Observational Studies. The trials explored outcomes related to systemic or functional imbalance by measuring the induction-to-abortion interval.

Research describes patterns observed in the studies regarding the rate and timing of successful expulsion. However, the evidence for this second-trimester use is more limited than for the labor induction studies. A significant portion of the data is derived from older research, and comparative evidence is lacking for certain study scenarios.


Evidence for Acute Use in Newborns with Congenital Heart Defects (Alprostadil)

The use of a different formulation of Prostin, which contains alprostadil, for supportive care in newborns who have specific congenital heart defects was evaluated in settings that require immediate, life-saving intervention. Due to the critical nature of these conditions, the evidence primarily comes from Descriptive Case Series and Acute Pharmacodynamic Studies that focus on rapid stabilization. These studies monitored outcomes related to systemic or functional imbalance, such as the continuous maintenance of the ductus arteriosus opening.

Findings describe patterns observed in the studies where treatment was associated with the maintenance of ductal patency. The research base for this specific use consists of numerous studies. Research describes the patterns observed during immediate stabilization.

Key Studies & References NICE Guideline: Induction of labour

Frequently Asked Questions (FAQ)

Common questions about Prostin (FAQ)


Q: Is Prostin the same kind of drug as other medicines used for the same purpose?

Prostin is a brand name used for two different active ingredients: Dinoprostone (a Prostaglandin E2 analog) and Alprostadil (a Prostaglandin E1 analog). While both belong to the larger family of prostaglandins—synthetic versions of naturally occurring compounds—they are different molecules and are associated with distinct, specific medical uses.


Q: What's the difference between Prostin and other prostaglandin drugs?

Prostin products contain either dinoprostone or alprostadil, which are two specific types of prostaglandins. According to official labeling, dinoprostone is specifically indicated for cervical ripening and labor induction in pregnant women. This focuses its use and distinguishes it from the indications and approved uses of other prostaglandin drugs.


Q: What are some common misunderstandings people have about Prostin's use?

A common point of confusion is that Prostin is a single medication; however, the name refers to products with two distinct ingredients, dinoprostone and alprostadil. These two active ingredients treat completely different conditions. Dinoprostone is used for procedures in adults (obstetrics), while alprostadil is used for temporary, supportive care in newborns with specific congenital heart defects.


Q: Do patients typically feel a difference right after Prostin is administered?

Official safety data for dinoprostone mentions several sensations that may occur shortly after administration. These can include a warm feeling in the vagina or the patient becoming aware of the uterine contractions that the medication is designed to induce. Patients are typically advised to communicate any unexpected or severe discomfort with the medical staff present during administration.


Q: How long does it take for the effects of Prostin to be noticed?

For dinoprostone formulations, the medication begins to absorb relatively quickly, with peak levels of its metabolites often seen within an hour of administration. The full clinical effect, such as preparing the cervix, can take longer. Regulatory documents describe a typical waiting period before any potential repeat administration may be considered.


Q: Is Prostin a medicine that is used only in the hospital?

Yes, official labeling mandates that Prostin must be administered exclusively in a hospital or clinic setting. This is because specialized obstetric or pediatric intensive care facilities and continuous monitoring of both the patient and the fetus or neonate must be immediately available during and after administration.


Q: Can Prostin be used for purposes other than those officially listed?

Official documentation only details the specific uses for which the medicine has been reviewed and approved by regulatory authorities. Official documentation strictly limits the drug's use to the indications for which it has been formally reviewed and approved.


Q: Is it normal for a patient's temperature to change after Prostin is given?

Yes, temperature changes are a commonly reported event, particularly with dinoprostone vaginal suppository use. Official safety data indicates that approximately half of the patients studied experienced temperature elevations (fever), which are often transient. These temperature changes are often transient and tend to subside following the conclusion of the treatment period.


Q: Why do official sources sometimes use different brand names for the same medicine as Prostin?

The active ingredients in Prostin, which are dinoprostone and alprostadil, are sold under various brand names globally, such as Cervidil and Prepidil. Different manufacturers or regional markets may use distinct brand names for the same chemical compound. The core chemical identity and regulatory purpose remain the same regardless of the brand.


Q: Does Prostin affect blood pressure in a noticeable way?

Official safety information for Prostin does include the potential for changes in blood pressure. For the alprostadil formulation, Hypotension (low blood pressure) is listed as a common adverse reaction. For dinoprostone, a small number of patients in studies exhibited transient decreases in diastolic blood pressure.


Q: Can Prostin cause digestive problems like nausea or vomiting?

Yes, the official documentation lists several types of digestive upset. For dinoprostone formulations, commonly reported side effects include nausea, vomiting, and diarrhea, with vomiting being one of the most frequent reactions observed in certain clinical studies.


Q: How often do patients have an allergic reaction to Prostin?

Official labeling documents post-marketing reports of serious and life-threatening hypersensitivity reactions, including anaphylaxis. The potential for an allergic reaction, including serious hypersensitivity, is listed as a critical safety consideration in official labeling. Because of this risk, the drug is not used in patients with a known hypersensitivity.


Q: What is the standard procedure if a side effect occurs after administration?

The standard procedure outlined in regulatory documents advises medical personnel to remove or discontinue the drug immediately if a serious or sustained adverse reaction occurs. This is followed by providing symptomatic and supportive therapy to manage the reaction. This requirement for specialized settings underscores the importance of medical supervision during administration.


Q: Can Prostin affect fertility later on?

Official labeling for the dinoprostone formulation notes that studies regarding the potential impairment of fertility have not been conducted. This is due to the drug's limited, specialized indications and the short duration of administration required. Preclinical studies examining long-term effects found no evidence of mutagenicity (changes to genetic material).


Q: What is the official recommendation regarding physical activity after receiving Prostin?

For dinoprostone vaginal formulations, official product information requires the patient to remain lying down (in a supine or lateral position) for a specified period, typically at least 30 minutes, after the administration. This position is required as part of the administration procedure defined in the official product information.


Q: Is there a maximum amount of time Prostin can be administered?

Yes, maximum use is strictly controlled by the formulation. For dinoprostone formulations, there are limits on the total amount that can be administered within a defined period, such as 24 hours. For alprostadil, its use is intended to be temporary and palliative, with official safety information noting that structural changes may occur with extended, continuous exposure.

How should Prostin be stored and disposed of?

Storage and Disposal of Prostin

Prostin requires mandatory cold chain storage to maintain the stability of its active ingredients. All formulations, including Prostin E2 and Prostin VR Pediatric, must be kept in a refrigerator at a temperature between 2°C and 8°C. It is strictly prohibited to freeze the product.

Stability and Handling

Diluted solutions, such as Prostin VR Pediatric infusions, must be used within 24 hours and then discarded. Prostin E2 Vaginal Gel requires a 30-minute period to warm to room temperature before administration and is for single use only.

Final Disposal

Consistent with regulatory guidelines, all unused or expired medicine, as well as waste material, must be disposed of in accordance with current local pharmaceutical waste requirements. The medication must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostin found in:

A-Z Index: